Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 May;40(5):1134–1138. doi: 10.1128/aac.40.5.1134

Protein binding of clindamycin in sera of patients with AIDS.

J F Flaherty Jr 1, G Gatti 1, J White 1, J Bubp 1, M Borin 1, J G Gambertoglio 1
PMCID: PMC163278  PMID: 8723453

Abstract

Patients with AIDS have altered pharmacokinetics of clindamycin compared with those of healthy control subjects. In an attempt to better understand these differences, we undertook a study of protein binding of clindamycin in sera of patients with AIDS. Fifteen patients with AIDS and 15 healthy volunteers were given a single 600-mg dose of clindamycin orally and intravenously, and serum samples were collected at three time points corresponding to high, midpoint, and low clindamycin concentrations. Protein binding was determined by ultrafiltration, and total and unbound clindamycin concentrations were measured with a gas chromatography assay. AIDS patients had alpha 1-acid glycoprotein values approximately twice those of healthy volunteers (mean +/- standard deviation, 103 +/- 27 versus 61 +/- 11 mg/dl; P = 0.001). Overall, serum protein binding levels were higher in AIDS patients (mean +/- standard deviation, 83 +/- 7 versus 78% +/- 8%; P = 0.0001), which is likely the result of increased alpha 1-acid glycoprotein levels in these patients. Total concentrations of clindamycin in plasma were significantly higher in AIDS patients at most time points studied, while unbound serum clindamycin concentrations did not differ among the groups at each sampling time after both oral and intravenous dosing. Increased protein binding may partly explain the altered pharmacokinetic disposition of clindamycin in AIDS patients; however, other factors cannot be excluded.

Full Text

The Full Text of this article is available as a PDF (192.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bilello J. A., Bilello P. A., Prichard M., Robins T., Drusano G. L. Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein. J Infect Dis. 1995 Mar;171(3):546–551. doi: 10.1093/infdis/171.3.546. [DOI] [PubMed] [Google Scholar]
  2. Dannemann B., McCutchan J. A., Israelski D., Antoniskis D., Leport C., Luft B., Nussbaum J., Clumeck N., Morlat P., Chiu J. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med. 1992 Jan 1;116(1):33–43. doi: 10.7326/0003-4819-116-1-33. [DOI] [PubMed] [Google Scholar]
  3. Flaherty J. F., Rodondi L. C., Guglielmo B. J., Fleishaker J. C., Townsend R. J., Gambertoglio J. G. Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens. Antimicrob Agents Chemother. 1988 Dec;32(12):1825–1829. doi: 10.1128/aac.32.12.1825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gatti G., Flaherty J., Bubp J., White J., Borin M., Gambertoglio J. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother. 1993 May;37(5):1137–1143. doi: 10.1128/aac.37.5.1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gordon R. C., Regamey C., Kirby W. M. Serum protein binding of erythromycin, lincomycin, and clindamycin. J Pharm Sci. 1973 Jul;62(7):1074–1077. doi: 10.1002/jps.2600620704. [DOI] [PubMed] [Google Scholar]
  6. Joshi A. M., Stein R. M. Altered serum clearance of intravenously administered clindamycin phosphate in patients with uremia. J Clin Pharmacol. 1974 Feb-Mar;14(2):140–144. doi: 10.1002/j.1552-4604.1974.tb02304.x. [DOI] [PubMed] [Google Scholar]
  7. Kays M. B., White R. L., Gatti G., Gambertoglio J. G. Ex vivo protein binding of clindamycin in sera with normal and elevated alpha 1-acid glycoprotein concentrations. Pharmacotherapy. 1992;12(1):50–55. [PubMed] [Google Scholar]
  8. Kremer J. M., Wilting J., Janssen L. H. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev. 1988 Mar;40(1):1–47. [PubMed] [Google Scholar]
  9. Lee B. L., Wong D., Benowitz N. L., Sullam P. M. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther. 1993 May;53(5):529–535. doi: 10.1038/clpt.1993.66. [DOI] [PubMed] [Google Scholar]
  10. Leigh D. A. Antibacterial activity and pharmacokinetics of clindamycin. J Antimicrob Chemother. 1981 Jun;7 (Suppl A):3–9. doi: 10.1093/jac/7.suppl_a.3. [DOI] [PubMed] [Google Scholar]
  11. Luft B. J., Hafner R., Korzun A. H., Leport C., Antoniskis D., Bosler E. M., Bourland D. D., 3rd, Uttamchandani R., Fuhrer J., Jacobson J. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med. 1993 Sep 30;329(14):995–1000. doi: 10.1056/NEJM199309303291403. [DOI] [PubMed] [Google Scholar]
  12. Martyn J. A., Abernethy D. R., Greenblatt D. J. Plasma protein binding of drugs after severe burn injury. Clin Pharmacol Ther. 1984 Apr;35(4):535–539. doi: 10.1038/clpt.1984.73. [DOI] [PubMed] [Google Scholar]
  13. Oie S., Jacobson M. A., Abrams D. I. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV) J Acquir Immune Defic Syndr. 1993 May;6(5):531–533. [PubMed] [Google Scholar]
  14. Peddie B. A., Dann E., Bailey R. R. The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin. Aust N Z J Med. 1975 Jun;5(3):198–202. doi: 10.1111/j.1445-5994.1975.tb04568.x. [DOI] [PubMed] [Google Scholar]
  15. Suh B., Craig W. A., England A. C., Elliott R. L. Effect of free fatty acids on protein binding of antimicrobial agents. J Infect Dis. 1981 Apr;143(4):609–616. doi: 10.1093/infdis/143.4.609. [DOI] [PubMed] [Google Scholar]
  16. Toma E., Fournier S., Dumont M., Bolduc P., Deschamps H. Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS: a randomized, double-blind pilot trial. Clin Infect Dis. 1993 Aug;17(2):178–184. doi: 10.1093/clinids/17.2.178. [DOI] [PubMed] [Google Scholar]
  17. Voulgari F., Cummins P., Gardecki T. I., Beeching N. J., Stone P. C., Stuart J. Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery, and infection. Br Heart J. 1982 Oct;48(4):352–356. doi: 10.1136/hrt.48.4.352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Williams D. N., Crossley K., Hoffman C., Sabath L. D. Parenteral clindamycin phosphate: pharmacology with normal and abnormal liver function and effect on nasal staphylococci. Antimicrob Agents Chemother. 1975 Feb;7(2):153–158. doi: 10.1128/aac.7.2.153. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES